Advanced

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).

Armstrong, Andrew J; Kaboteh, Reza; Carducci, Michael A; Damber, Jan-Erik; Stadler, Walter M; Hansen, Mats; Edenbrandt, Lars LU ; Forsberg, Göran; Nordle, Orjan and Pili, Roberto, et al. (2014) In Urologic Oncology 32(8). p.1308-1316
Abstract
Drug development and clinical decision making for patients with metastatic prostate cancer (PC) have been hindered by a lack of quantitative methods of assessing changes in bony disease burden that are associated with overall survival (OS). Bone scan index (BSI), a quantitative imaging biomarker of bone tumor burden, is prognostic in men with metastatic PC. We evaluated an automated method for BSI calculation for the association between BSI over time with clinical outcomes in a randomized double-blind trial of tasquinimod (TASQ) in men with metastatic castration-resistant PC (mCRPC).
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Urologic Oncology
volume
32
issue
8
pages
1308 - 1316
publisher
Elsevier
external identifiers
  • pmid:25240761
  • wos:000346627300031
  • scopus:84925940426
ISSN
1873-2496
DOI
10.1016/j.urolonc.2014.08.006
language
English
LU publication?
yes
id
bd341b2a-9021-40fc-afd0-7edcb89600c4 (old id 4691128)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25240761?dopt=Abstract
date added to LUP
2014-10-08 15:15:17
date last changed
2017-11-05 03:03:17
@article{bd341b2a-9021-40fc-afd0-7edcb89600c4,
  abstract     = {Drug development and clinical decision making for patients with metastatic prostate cancer (PC) have been hindered by a lack of quantitative methods of assessing changes in bony disease burden that are associated with overall survival (OS). Bone scan index (BSI), a quantitative imaging biomarker of bone tumor burden, is prognostic in men with metastatic PC. We evaluated an automated method for BSI calculation for the association between BSI over time with clinical outcomes in a randomized double-blind trial of tasquinimod (TASQ) in men with metastatic castration-resistant PC (mCRPC).},
  author       = {Armstrong, Andrew J and Kaboteh, Reza and Carducci, Michael A and Damber, Jan-Erik and Stadler, Walter M and Hansen, Mats and Edenbrandt, Lars and Forsberg, Göran and Nordle, Orjan and Pili, Roberto and Morris, Michael J},
  issn         = {1873-2496},
  language     = {eng},
  number       = {8},
  pages        = {1308--1316},
  publisher    = {Elsevier},
  series       = {Urologic Oncology},
  title        = {Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).},
  url          = {http://dx.doi.org/10.1016/j.urolonc.2014.08.006},
  volume       = {32},
  year         = {2014},
}